Gan&Lee | Briefing, News, Analysis, Research, Data

Gan&Lee

Gan&Lee is a high-tech biopharmaceutical enterprise integrating research

Gan & Lee Pharmaceutical Co., Ltd. was established in 1998, is a high-tech biopharmaceutical enterprise integrating research, development, production and sales. The company is a leading company at home and abroad in the development, research and production of biosynthetic human insulin and its analogs, and is a professional company focusing on biosynthetic human insulin analogs.

Sector

Healthcare

Industry

Biotech/Pharma

Sub-industry

Founded

Jun 1, 1998

HQ location

Beijing, China

Legal name

Beijing Gan & Lee Biotechnology Co., Ltd.

Website

http://www.ganlee.com/

jianjun.gan@ganlee.com

Employees

1001-5000

All
News
Analysis
Research

Briefing Jan 30, 2023 10:44 AM · Healthcare

Levostar Completes Pre-A Financing Round to Further Invest in CGT

Briefing Jun 22, 2022 04:19 PM · Technology | Consumer Discretionary | Healthcare

Zhaolihong, former member of the Party committee and vice president of Agricultural Bank of China Hebei Branch, was "double opened"

In-depth

Healthcare

Chinese Company Turned the Tables on Domestic Cell Culture Media Market

In this article, EqualOcean mainly introduce the history, competition, lead company, future trend in domestic cell culture media industry.

Updated 12 hours ago

Briefing Mar 10, 2022 03:49 PM · Technology | Consumer Staples | Healthcare

Liaoning Province held a working meeting to promote the listing of enterprises and launched the doubling plan for the listing of enterprises

Briefing Feb 23, 2022 06:59 PM · Technology | Healthcare | Financials

Pioneer fund welcomes the new general manager and the executive deputy general manager will no longer act as the general manager

Research

Healthcare

Digital Therapeutics - Revolution of the healthcare system

Nov 16, 2022 05:19 PM

Research

Healthcare

2022 China AI Health 30 Report

Nov 07, 2022 04:27 PM

Research

Healthcare

2022 China’s Healthcare Industry: An Introductory Handbook

Aug 29, 2022 05:45 PM

Research

Technology, Healthcare, Financials

WIA2020 | 30 Tech Entrepreneurs in China

Apr 22, 2021 03:11 PM

Briefing Dec 10, 2021 05:49 PM · Technology | Consumer Staples | Consumer Discretionary

Haipurui: it plans to publicly issue corporate bonds of no more than RMB 1.5 billion to professional investors

Briefing Dec 06, 2021 04:49 PM · Technology | Consumer Staples | Healthcare

Humon shares: the 2021 ESOP has not yet started to purchase the company's shares

Briefing Nov 30, 2021 04:09 PM · Technology | Consumer Staples | Healthcare

Stellar Technology: 34.6 million shares pledged and extended by the controlling shareholder

Briefing Nov 26, 2021 11:38 AM · Healthcare

Ganli pharmaceutical won the bid for centralized procurement of insulin glargine injection

Healthcare

Real And Best Nets Over CNY 200 Mn in Series A+

Gene therapy company Real And Best accelerates to promote pipelines covering genetic disease, metabolism, and aging

Updated 11 hours ago

In-depth

Healthcare

Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis

‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’

Jan 30, 2023 02:13 PM

Briefing Nov 26, 2021 11:30 AM

Special national collection of insulin: Ganli pharmaceutical Ganjing and asparagus insulin all reported the lowest prices: 48.71 yuan and 19.98 yuan

Briefing Nov 17, 2021 06:49 PM

Robin Li: Baidu has become the world's largest automated driving service provider.

Briefing Oct 12, 2021 05:23 PM · Technology | Healthcare | Automotive

Urban investment holding: the newly signed amount of real estate projects in the third quarter was about 304.3 million yuan

Healthcare

Biopharma Company IASO Bio Nets Nearly CNY 500 Mn in Series C1

The Chinese leading cell therapy company IASO Bio will soon launch its first commercialized CAR-T product

Jan 18, 2023 10:43 AM

Insight

Healthcare

Opportunities and Challenges Hidden in the CGT Industry in China

CGT (Cell and Gene Therapy) is a sector with high growth potential. CAR-T, as one of the main CGT currently, presents great value for both doctors and patients. This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.

Jan 17, 2023 05:48 PM

Briefing Sep 10, 2021 06:57 PM · Technology | Healthcare | Financials

Xin Guobin: accelerate the promotion of robots such as family services, education and entertainment

Briefing Aug 24, 2021 05:28 PM · Technology | Consumer Staples | Healthcare

Huitai medical: net profit in the first half of the year increased by 186.24% year-on-year

Briefing Aug 20, 2021 05:48 PM · Healthcare

During the 14th Five Year Plan period, China will restore 230 million mu of degraded grassland

Briefing Jul 23, 2021 10:13 AM · Healthcare

Pharmaceutical and biological stocks fell sharply in early trading

EqualOcean Analysis